Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4285468 | 0.92 | SLC6A2 (0.31) | — | |
| SCHEMBL2589725 | 0.78 | CDK9 (0.40) | — | |
| SCHEMBL562058 | 0.75 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL16292529 | 0.74 | ALOX5 (0.39) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1434883 | 0.72 | CES2 (0.33) | CES2 | |
| SCHEMBL1983631 | 0.70 | — | — | |
| SCHEMBL14733413 | 0.70 | — | — | |
| SCHEMBL343584 | 0.70 | ALOX5 (0.35) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL343583 | 0.70 | ALOX5 (0.35) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1498383 | 0.68 | ALOX5 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086853-A1 | Therapeutic Compounds | BROWN WILLIAM | 2011-04-14 | — | — | US | disclosed |
| US-7615642-B2 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-7550495-B2 | Compounds, compositions containing them, preparation thereof and uses thereof I | ASTRAZENECA AB (SE) | 2009-06-23 | — | — | US | disclosed |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264490-A1 | Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I | F12, C1S, C1R | CES2 1311/4885MEN1 732/4885HTT 2498/4885 |
| US-20110086853-A1 | Therapeutic Compounds | OPRL1, F12, F3 | CES2 1602/4885MEN1 1668/4885HTT 1515/4885 |
| US-20070244092-A1 | N-Cyclopropyl-1-{[2-(1,1-difluoroethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-benzimidazol-5-yl]sulfonyl}-1H-pyrrole-3-carboxamide; for pain management | OPRM1, OPRL1, OPRK1 | CES2 2263/4885MEN1 3468/4885HTT 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.